The FDA has approved xT CDx, a 648-gene next-generation sequencing assay for solid tumor profiling, and companion diagnostic for patients with colorectal cancer.
January 2023 Developing next-generation immunotherapies that address cancer immune resistance KA Disclaimers and other information Cautionary. | January 5, 2023